Clinical Trial Update: A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update for GNC-039, a tetra-specific antibody, in relapsed/refractory or metastatic solid tumors; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma
• Solid Tumors

Drugs mentioned

• GNC-039 (GNC-039)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Recurrent Glioma, Solid Tumor | Phase 1 | Status: RECRUITING